
浏览全部资源
扫码关注微信
新疆维吾尔自治区人民医院肿瘤科,新疆 乌鲁木齐 830000
韩忠诚,E-mail:2362978928@qq.com
纸质出版日期:2024-11-25,
收稿日期:2023-09-05,
移动端阅览
苏莹,马丽丽,柳江等.miR-519d在非小细胞肺癌脑转移中的作用及机制[J].局解手术学杂志,2024,33(11):974-979.
SU Ying,MA Li-li,LIU Jiang,et al.Role and mechanism of miR-519d in brain metastasis of non-small cell lung cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(11):974-979.
苏莹,马丽丽,柳江等.miR-519d在非小细胞肺癌脑转移中的作用及机制[J].局解手术学杂志,2024,33(11):974-979. DOI: 10.11659/jjssx.09E023022.
SU Ying,MA Li-li,LIU Jiang,et al.Role and mechanism of miR-519d in brain metastasis of non-small cell lung cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(11):974-979. DOI: 10.11659/jjssx.09E023022.
目的
2
探究miR-519d在非小细胞肺癌(NSCLC)脑转移(BM)中的作用及其机制。
方法
2
采用RT-PCR检测miR-519d在伴有BM的NSCLC患者和无BM的患者癌旁正常肺组织、NSCLC肺组织、NSCLC脑组织,人NSCLC细胞系(SK-MES-1、NCI-H226、NCIH1299和NCL-H820)、正常人支气管上皮细胞(HBECs)、人脑微血管内皮细胞(HBMECs)及正常人星形胶质细胞(NHA)中的表达。将过表达miR-519d慢病毒(OE-miR-519d-LV)或空载体慢病毒(NC-LV)转染至NSCLC细胞系NCI-H1299中,作为OE-miR-519d-LV组和NC-LV组;联合转染OE-miR-519d-LV与pcDNA3.1-HER3的细胞作为OE-miR-519d-LV+pcDNA3.1-HER3组。将OE-miR-519d-LV组和NC-LV组细胞经心脏注射至裸鼠体内,以构建伴BM的NSCLC动物模型,并按注射细胞的不同将小鼠分为Ctrl组与miR-519d组。使用生物发光成像系统观察NCI-H1299细胞在小鼠大脑中的转移情况。CCK-8法检测OE-miR-519d-LV组和NC-LV组中NCI-H1299细胞的增殖情况。采用HBMECs和NHA包被的Transwell小室,以建立体外血脑屏障(BBB)细胞模型,并检测OE-miR-519d-LV组和NC-LV组NCI-H1299细胞跨内皮细胞的迁移能力。Western blot检测各组细胞中上皮间质转化(EMT)相关蛋白MMP-2、MMP-9、E-cadherin、N-cadherin和Vimentin的表达。生物信息学技术分析miR-519d与HER3的潜在结合位点,双荧光素酶基因报告实验验证两者的靶向调控关系。
结果
2
与癌旁正常肺组织相比,miR-519d在NSCLC肺组织和NSCLC脑组织中的表达降低(
P
<
0.05);与NSCLC肺组织相比,NSCLC脑组织中miR-519d表达降低(
P
<
0.05)。与HBECs相比,miR-519d在NSCLC细胞系中的表达降低(
P
<
0.05),且miR-519d在NCI-H1299、NCI-H226和NCL-H820细胞中的表达水平低于SK-MES-1细胞(
P
<
0.05)。与Ctrl组裸鼠相比,miR-519d组裸鼠的BM发生率更低,生存时间更长,差异有统计学意义(
P
<
0.05)。与NC-LV组细胞相比,OE-miR-519d-LV组NCI-H1299细胞增殖活力、跨内皮细胞迁移能力及MMP-2、MMP-9、N-cadherin和Vimentin蛋白表达降低(
P
<
0.05),而E-cadherin蛋白表达升高(
P
<
0.05)。miR-519d可靶向调控HER3蛋白表达。与OE-miR-519d-LV组相比,OE-miR-519d-LV+pcDNA3.1-HRE3组细胞的迁移能力升高(
P
<
0.05),MMP-2、MMP-9、N-cadherin和Vimentin蛋白表升高(
P
<
0.05),而E-cadherin表达降低(
P
<
0.05)。
结论
2
miR-519d在伴有BM的NSCLC中表达水平降低,上调其表达可通过靶向调控HER3来抑制肿瘤的BM。
Objective
2
To investigate the role and mechanism of miR-519d in brain metastasis (BM) of non-small cell lung cancer (NSCLC).
Methods
2
RT-PCR was used to detect the expression of miR-519d in normal lung tissues adjacent to cancer, NSCLC lung tissues, NSCLC brain tissues in NSCLC patients with or without BM,human NSCLC cell lines (SK-MES-1,NCI-H226,NCI-H1299,and NCL-H820),normal human bronchial epithelial cells (HBECs),human brain microvascular endothelial cells (HBMECs),and normal human astrocytes (NHA). NSCLC cell line NCI-H1299 was transfected with either miR-519d overexpression lentivirus (OE-miR-519d-LV) or empty vector lentivirus (NC-LV),and set as the OE-miR-519d-LV group and the NC-LV group;cells co-transfected with OE-miR-519d-LV and pcDNA3.1-HER3 were designated as the OE-miR-519d-LV+pcDNA3.1-HER3 group. The cells of the OE-miR-519d-LV group and the NC-LV group were injected intracardially into nude mice to establish an animal model of NSCLC with BM, and the mice were divided into the Ctrl group and the miR-519d group based on the injected cells.Bioluminescence imaging was used to observe NCI-H1299 cell metastasis in the brain of mice. The CCK-8 assay was used to determine the proliferation of NCI-H1299 cells in the OE-miR-519d-LV group and the NC-LV group. An in vitro blood-brain barrier (BBB) model was established using HBMECs and NHA-coated Transwell chambers, and the transendothelial migration ability of NCI-H1299 cells was detected. Western blot was used to detect the expression of epithelial-mesenchymal transition (EMT)-related proteins of MMP-2, MMP-9, E-cadherin, N-cadherin, and Vimentin in each group. Bioinformatics analysis was used to identify the potential binding sites between miR-519d and HER3,and their targeted regulatory relationship was validated by dual-luciferase gene reporter assays.
Results
2
Compared with the normal lung tissues adjacent to cancer, m
iR-519d expression was reduced in the NSCLC lung tissues and NSCLC brain tissues (
P
<
0.05); miR-519d expression was lower in NSCLC brain tissues compared with the NSCLC lung tissues (
P
<
0.05). Compared with HBECs, miR-519d expression was reduced in NSCLC cell lines (
P
<
0.05), with lower levels in NCI-H1299, NCI-H226, and NCL-H820 cells compared with SK-MES-1 cells (
P
<
0.05). Nude mice in the miR-519d group had a lower incidence of BM and longer survival compared with those in the Ctrl group, with statistically significant differences (
P
<
0.05). Compared with the NC-LV group,NCI-H1299 cells in the OE-miR-519d-LV group showed decreases in the proliferation viability, transendothelial migration ability, and protein expression of MMP-2, MMP-9, N-cadherin, and Vimentin (
P
<
0.05),and an increase in the protein expression of E-cadherin (
P
<
0.05). miR-519d had a targeted regulatory effect on HER3 protein expression. Compared with the OE-miR-519d-LV group, the migration ability of cells in the OE-miR-519d-LV+pcDNA3.1-HRE3 group was increased (
P
<
0.05), the protein expression of MMP-2, MMP-9, N-cadherin and Vimentin was increased (
P
<
0.05), and the expression of E-cadherin was decreased (
P
<
0.05).
Conclusion
2
miR-519d expression is reduced in NSCLC with BM, and its upregulation can inhibit the BM of NSCLC by targeting HER3.
非小细胞肺癌miR-519d人表皮生长因子受体3脑转移
non-small cell lung cancermiR-519dhuman epidermal growth factor receptor 3brain metastasis
李雨奇,罗晓燕,张鹏博,等. 双期18F-FDG PET/CT原发灶影像组学对非小细胞肺癌淋巴结转移的预测价值[J].局解手术学杂志,2023,32(2):142-145.doi:10.11659/jjssx.07E022056http://dx.doi.org/10.11659/jjssx.07E022056.
Yousefi M,Bahrami T,Salmaninejad A,et al. Lung cancer-associated brain metastasis: molecular mechanisms and therapeutic options[J]. Cell Oncol (Dordr), 2017,40(5):419-441.doi:10.1007/s13402-017-0345-5http://dx.doi.org/10.1007/s13402-017-0345-5.
Yang Y, Deng L, Yang Y, et al. Efficacy and safety of combined brain radiotherapy and immunotherapy in non-small-cell lung cancer with brain metastases: a systematic review and meta-analysis[J]. Clin Lung Cancer,2022,23(2):95-107.doi:10.1016/j.cllc.2021.06.009http://dx.doi.org/10.1016/j.cllc.2021.06.009.
Iqbal MA, Arora S, Prakasam G, et al. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance[J]. Mol Aspects Med, 2019,70:3-20. doi: 10.1016/j.mam.2018.07.003http://dx.doi.org/10.1016/j.mam.2018.07.003.
Saliminejad K,Khorram Khorshid HR,Soleymani Fard S,et al.An overview of microRNAs:biology,functions, therapeutics,and analysis methods[J].J Cell Physiol,2019,234(5):5451-5465.doi:10.1002/jcp.27486http://dx.doi.org/10.1002/jcp.27486.
Tang L, Yuan Y, Zhai H, et al. MicroRNA-125b-5p correlates with prognosis and lung adenocarcinoma progression[J]. Front Mol Biosci, 2022,8:788690. doi:10.3389/fmolb.2021.788690http://dx.doi.org/10.3389/fmolb.2021.788690.
Su WZ, Ren LF. MiRNA-199 inhibits malignant progression of lung cancer through mediating RGS17[J]. Eur Rev Med Pharmacol Sci, 2019,23(8):3390-3400. doi: 10.26355/eurrev_201904_17703http://dx.doi.org/10.26355/eurrev_201904_17703.
Xie Y, Xue C, Guo S, et al. MicroRNA-520a suppresses pathogenesis and progression of non-small-cell lung cancer through targeting the RRM2/Wnt axis[J]. Anal Cell Pathol (Amst), 2021,2021:9652420. doi: 10.1155/2021/9652420http://dx.doi.org/10.1155/2021/9652420.
Chu C, Liu X, Bai X, et al. MiR-519d suppresses breast cancer tumorigenesis and metastasis via targeting MMP3[J]. Int J Biol Sci, 2018,14(2):228-236. doi: 10.7150/ijbs.22849http://dx.doi.org/10.7150/ijbs.22849.
Zhang D,Yang XJ,Luo QD,et al.Transcription factor p53-mediated activation of miR-519d-3p and downregulation of E2F1 attenuates prostate cancer growth and metastasis[J]. Cancer Gene Ther, 2022,29(7):1001-1011.doi:10.1038/s41417-021-00405-6http://dx.doi.org/10.1038/s41417-021-00405-6.
Yue H,Tang B,Zhao Y,et al.MIR-519d suppresses the gastric cancer epithelial-mesenchymal transition via Twist1 and inhibits Wnt/β-catenin signaling pathway[J].Am J Transl Res, 2017,9(8):3654-3664.doi:10.1002/jcb.26270http://dx.doi.org/10.1002/jcb.26270.
Choi JY, Seok HJ, Kim RK, et al. miR-519d-3p suppresses tumorigenicity and metastasis by inhibiting Bcl-w and HIF-1α in NSCLC[J]. Mol Ther Oncolytics, 2021,17(22):368-379. doi:10.1016/j.omto.2021.06.015http://dx.doi.org/10.1016/j.omto.2021.06.015.
Wang A, Zhang H, Wang J, et al. MiR-519d targets HER3 and can be used as a potential serum biomarker for non-small cell lung cancer[J].Aging (Albany NY),2020,12(6):4866-4878.doi:10.18632/aging.102908http://dx.doi.org/10.18632/aging.102908.
Xing F,Sharma S,Liu Y,et al.miR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-α[J].Oncogene, 2015,34(37):4890-4900. doi: 10.1038/onc.2014.412http://dx.doi.org/10.1038/onc.2014.412.
Zhang G,Hu Y,Yuan W,et al. miR-519d-3p overexpression inhibits P38 and PI3K/AKT pathway via targeting VEGFA to attenuate the malignant biological behavior of non-small cell lung cancer[J]. Onco Targets Ther, 2020,10(13):10257-10266. doi:10.2147/OTT.S252795http://dx.doi.org/10.2147/OTT.S252795.
Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis[J]. J Hematol Oncol, 2022,15(1):129-136. doi: 10.1186/s13045-022-01347-8http://dx.doi.org/10.1186/s13045-022-01347-8.
Majidpoor J, Mortezaee K. Steps in metastasis: an updated review[J]. Med Oncol, 2021,38(1):3-12. doi: 10.1007/s12032-020-01447-whttp://dx.doi.org/10.1007/s12032-020-01447-w.
Gandullo-Sánchez L, Ocaña A, Pandiella A. HER3 in cancer: from the bench to the bedside[J]. J Exp Clin Cancer Res, 2022,41(1):310-318. doi: 10.1186/s13046-022-02515-xhttp://dx.doi.org/10.1186/s13046-022-02515-x.
0
浏览量
1
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621